Department of Anesthesiology and Reanimation, Faculty of Medicine, İstanbul Medipol University, İstanbul, Turkey.
Turk J Med Sci. 2022 Aug;52(4):1311-1321. doi: 10.55730/1300-0144.5437. Epub 2022 Aug 10.
Autologous transfusion using a cell saver system has been used in liver transplantation with controversial outcomes. Its efficiency in patients with massive intraoperative transfusion has not been studied yet. This study aimed to evaluate effect of cell salvage (CS) on intraoperative bleeding and transfusion practices in liver transplantation with massive intraoperative transfusion.
Consecutive patients aged ≥18 years with intraoperative massive blood transfusion (≥ 6 units) between March 2014 and September 2020 were included. Patients subjected to CS were grouped as CS, whereas other patients were grouped as control. Number of transfused red blood cells was study's primary outcome.
There were 38 and 32 patients in CS and control groups, respectively. Median blood loss was significantly lower in CS group than in control group (2500 mL vs. 4000 mL, p = 0.010). There were significantly more transfusions of red blood cells, fresh frozen plasma, platelets, and cryoprecipitates in CS group (p < 0.05). Postoperative median hemoglobin levels were determined as 4.8 g/dL and 8.2 g/dL in CS and control groups (p < 0.001). The decrease in postoperative hemoglobin levels compared to preoperative values was significantly higher in the CS group (p < 0.001). The mortality rate in postoperative first year was significantly higher in CS group than in control group (36.8% vs. 12.5%, p = 0.041).
Use of CS in patients undergoing liver transplantation with massive intraoperative transfusion did not improve clinical and transfusion-related outcomes. In conclusion, its usage can be questionable given the absence of any clinical benefit and presence of poor outcomes.
使用血液回收机进行自体输血已应用于肝移植,但结果存在争议。其在术中大量输血患者中的应用效果尚未得到研究。本研究旨在评估血液回收(CS)对术中大量输血肝移植术中出血和输血的影响。
纳入 2014 年 3 月至 2020 年 9 月术中大量输血(≥6 单位)的连续≥18 岁患者。使用 CS 的患者分为 CS 组,其他患者分为对照组。输血量为研究的主要结果。
CS 组和对照组分别有 38 例和 32 例患者。CS 组的中位出血量明显低于对照组(2500 毫升比 4000 毫升,p = 0.010)。CS 组红细胞、新鲜冷冻血浆、血小板和冷沉淀的输注量明显较多(p < 0.05)。CS 组和对照组术后中位血红蛋白水平分别为 4.8 g/dL 和 8.2 g/dL(p < 0.001)。CS 组术后血红蛋白水平较术前下降幅度明显更高(p < 0.001)。CS 组术后第一年的死亡率明显高于对照组(36.8%比 12.5%,p = 0.041)。
在术中大量输血的肝移植患者中使用 CS 并不能改善临床和输血相关结局。总之,由于缺乏临床获益和较差的预后,其使用可能存在疑问。